Coherus Oncology, Inc. (CHRS): Insider Trading, Congress Trades & Research | Tormere

CHRS

$0.85+5.54%visit website

Coherus Oncology, Inc.

Market Cap

$131M

Live price × SEC shares (Jul 31, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.00

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

2.6

TTM to Jun 2026 · revenue

P/B

2.2

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	11,571	12,748	12,310	14,307	50,936
Cost of revenue	3,721	4,045	3,814	4,242	15,822
Research & development	27,252	30,974	21,543	21,442	101,211
Selling, general & administrative	24,931	23,609	23,104	20,954	92,598
Operating income	(44,333)	(45,880)	(36,151)	(32,331)	(158,695)
Interest expense	2,325	2,249	2,186	2,323	9,083
Pretax income	(44,517)	(46,347)	(36,935)	(33,347)	(161,146)
Net income	(35,531)	(37,643)	(38,327)	(20,631)	(132,132)
EPS (basic) ($)	(0.31)		(0.28)	(0.13)	(1.05)
EPS (diluted) ($)	(0.31)		(0.28)	(0.13)	(1.05)
Weighted avg. shares (basic)	116,229		136,398	154,817
Weighted avg. shares (diluted)	116,229		136,398	154,817

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 5, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 50 more quarters, back to Mar 2013, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

Coherus Oncology, Inc. (CHRS) stock price, news, quote and history

Yahoo Finance Singapore · 2026-11-03

Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know

Yahoo · 2026-11-02

Gap-Up and Gap-Down Stocks in the Oct. 29, 2026 Session

ChartMill · 2026-10-29

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga · 2026-10-29

HC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7

Benzinga · 2026-10-29

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga · 2026-10-29

Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer Transcript

SeekingAlpha · 2026-10-29

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

Yahoo · 2026-10-29

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

Yahoo · 2026-10-28

Coherus to Participate in Upcoming Investor Conferences

Yahoo · 2026-10-27

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

Yahoo · 2026-10-26

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

Yahoo · 2026-10-14

Eligible shareholders may share proceeds from Coherus' assets tied to similar medicines. The sale process has begun.

Stock Titan · 2026-09-23

Coherus will give eligible holders rights to cash from former assets—but they may expire unpaid

Stock Titan · 2026-08-17

Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript

Yahoo Finance · 2026-08-13

Informational purposes only, not investment advice.